The Prostate

Cover image for Vol. 73 Issue 9

June 2013

Volume 73, Issue 9

Pages 905–1015

  1. Original Articles

    1. Top of page
    2. Original Articles
    1. Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality (pages 905–912)

      E. Sophie Spencer, Richard B. Johnston, Ryan R. Gordon, Jared M. Lucas, Cigdem Himmetoglu Ussakli, Antonio Hurtado-Coll, Shiv Srivastava, Peter S. Nelson and Christopher R. Porter

      Version of Record online: 17 JAN 2013 | DOI: 10.1002/pros.22636

    2. Thermotherapy using magnetic cationic liposomes powerfully suppresses prostate cancer bone metastasis in a novel rat model (pages 913–922)

      Daichi Kobayashi, Noriyasu Kawai, Shinya Sato, Taku Naiki, Kenji Yamada, Takahiro Yasui, Keiichi Tozawa, Takeshi Kobayashi, Satoru Takahashi and Kenjiro Kohri

      Version of Record online: 17 JAN 2013 | DOI: 10.1002/pros.22637

    3. Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases (pages 932–940)

      Sandy R. Larson, Xiaotun Zhang, Ruth Dumpit, Ilsa Coleman, Bryce Lakely, Martine Roudier, Celestia S. Higano, Lawrence D. True, Paul H. Lange, Bruce Montgomery, Eva Corey, Peter S. Nelson, Robert L. Vessella and Colm Morrissey

      Version of Record online: 17 JAN 2013 | DOI: 10.1002/pros.22639

    4. Impact of CXCL1 overexpression on growth and invasion of prostate cancer cell (pages 941–951)

      Roberto Benelli, Sara Stigliani, Simona Minghelli, Sebastiano Carlone and Nicoletta Ferrari

      Version of Record online: 17 JAN 2013 | DOI: 10.1002/pros.22640

    5. A novel canine model for prostate cancer (pages 952–959)

      Jill M. Keller, George R. Schade, Kimberly Ives, Xu Cheng, Thomas J. Rosol, Morand Piert, Javed Siddiqui, William W. Roberts and Evan T. Keller

      Version of Record online: 17 JAN 2013 | DOI: 10.1002/pros.22642

      Corrected by:

      Erratum: Erratum

      Vol. 74, Issue 12, 1249, Version of Record online: 17 JUL 2014

    6. Consumption of deep-fried foods and risk of prostate cancer (pages 960–969)

      Marni Stott-Miller, Marian L. Neuhouser and Janet L. Stanford

      Version of Record online: 17 JAN 2013 | DOI: 10.1002/pros.22643

    7. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin (pages 970–978)

      Jason Gee, Howard Bailey, KyungMann Kim, Jill Kolesar, Tom Havighurst, Kendra D. Tutsch, William See, Michael B. Cohen, Nick Street, Leon LeVan, David Jarrard and George Wilding

      Version of Record online: 17 JAN 2013 | DOI: 10.1002/pros.22644

    8. Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer (pages 979–985)

      Farshid Dayyani, Andreas Varkaris, John C. Araujo, Jian H. Song, Tanushree Chatterji, Geralyn C. Trudel, Christopher J. Logothetis and Gary E. Gallick

      Version of Record online: 31 JAN 2013 | DOI: 10.1002/pros.22645

    9. Combination effects of dietary soy and methylselenocysteine in a mouse model of prostate cancer (pages 986–995)

      Merrill J. Christensen, Trevor E. Quiner, Heather L. Nakken, Edwin D. Lephart, Dennis L. Eggett and Paul M. Urie

      Version of Record online: 6 FEB 2013 | DOI: 10.1002/pros.22646

    10. A mouse model of chronic prostatic inflammation using a human prostate cancer-derived isolate of Propionibacterium acnes (pages 1007–1015)

      Debika Biswal Shinohara, Ajay M. Vaghasia, Shu-Han Yu, Tim N. Mak, Holger Brüggemann, William G. Nelson, Angelo M. De Marzo, Srinivasan Yegnasubramanian and Karen S. Sfanos

      Version of Record online: 6 FEB 2013 | DOI: 10.1002/pros.22648